Microeconornic surplus in health care: applied economic theory in health care in four European countries

被引:1
作者
Walzer, S. [1 ]
Nuijten, M. [2 ]
Wiesner, C. [3 ]
Kaier, K. [4 ]
Johansson, P-O. [5 ]
Oertel, S. [3 ]
机构
[1] MArS Market Access & Pricing Strategy UG Hb, D-79576 Weil Am Rhein, Germany
[2] Ars Accessus Med, Amsterdam, Netherlands
[3] F Hoffmann La Roche & Cie AG, Basel, Switzerland
[4] Univ Med Ctr Freiburg, Inst Med Biometry & Med Informat, Freiburg, Germany
[5] Stockholm Sch Econ, S-11383 Stockholm, Sweden
来源
FRONTIERS IN PHARMACOLOGY | 2013年 / 4卷
关键词
microeconomic surplus; convenience; health care; health care policy;
D O I
10.3389/fphar.2013.00017
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: In economic theory economic surplus refers to two related quantities: Consumer and producer surplus. Applying this theory to health care "convenience" could be one way how consumer benefits might manifest itself. Methods: Various areas of economic surplus were identified and subsequently screened and analyzed in Germany, Spain,The Netherlands, and the UK: Cesarean births, emergency room visits (nights or weekends), drug availability after test results, and response surplus. A targeted literature search was being conducted to identify the associated costs. Finally the economic surplus (convenience value) was calculated. Results: The economic surplus for different health care areas was being calculated. The highest economic surplus was obtained for the example of response surplus IVF-treatments in The Netherlands. Conclusion: The analyzed examples in this article support the underlying hypothesis for this research: "Value of convenience defined as the consumer surplus in health care can be shown in different health care settings." Again, this hypothesis should be accepted as a starting point in this research area and hence further primary research is strongly recommended in order to fully proof this concept.
引用
收藏
页数:6
相关论文
共 16 条
  • [1] [Anonymous], NAT COMPR CANC NETW
  • [2] [Anonymous], 2004, FERT ASS TREATM PEOP
  • [3] Assisted Reproductive Technology, 2009, SUCC RAT NAT SUMM FE
  • [4] Cabral L.M. B., 2002, INTRO IND ORG
  • [5] Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib
    Carey, Kendall D.
    Garton, Andrew J.
    Romero, Maria S.
    Kahler, Jennifer
    Thomson, Stuart
    Ross, Sarajane
    Park, Frances
    Haley, John D.
    Gibson, Neil
    Sliwkowski, Mark X.
    [J]. CANCER RESEARCH, 2006, 66 (16) : 8163 - 8171
  • [6] Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    D'Addario, G.
    Frueh, M.
    Reck, M.
    Baumann, P.
    Klepetko, W.
    Felip, E.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : v116 - v119
  • [7] SUPPLY-SIDE AND DEMAND-SIDE COST-SHARING IN HEALTH-CARE
    ELLIS, RP
    MCGUIRE, TG
    [J]. JOURNAL OF ECONOMIC PERSPECTIVES, 1993, 7 (04) : 135 - 151
  • [8] European Medicine Agency (EMA), 2012, SUMM PROD CHAR ERL T
  • [9] European Medicine Agency (EMA), 2012, SUMM PROD CHAR GEF I
  • [10] Cost-effectiveness of seven IVF strategies: results of a Markov decision-analytic model
    Fiddelers, Audrey A. A.
    Dirksen, Carmen D.
    Dumoulin, John C. M.
    van Montfoort, Aafke P. A.
    Land, Jolande A.
    Janssen, J. Marij
    Evers, Johannes L. H.
    Severens, Johan L.
    [J]. HUMAN REPRODUCTION, 2009, 24 (07) : 1648 - 1655